Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial

Graf et al., 2025

Rosnilimab, a Depleter and Agonist Antibody Targeting PD-1+ T Cells, in Clinical Development for Ulcerative Colitis, Reduces Pathogenic PD-1+ T Cells and Inflammatory Cytokine Secretion in Patient Blood and in a Mouse Model of Colitis

Soroosh et al., 2025

Imsidolimab, an IL-36 Receptor Antagonist, was Effective and Well-Tolerated for Treatment, Maintenance of Response, and Prevention of Flares in Patients with Generalized Pustular Psoriasis: Results from the Phase 3 Trials, GEMINI-1 and GEMINI-2

Reich et al., 2024

ANB032, a BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology

Muench et al., 2024

ANB032, an Investigational BTLA Agonist Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and Prolonged Survival in a Mouse Model of Graph versus Host Disease (GvHD)

Hare et al., 2024

ANB032, an Investigational BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis (AD) Pathophysiology

Soroosh et al., 2024

Rosnilimab, a PD-1 Agonist Antibody that Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling

Parmley et al., 2024

Optimizing PD-1 Agonist Signaling With Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

Parmley et al., 2024

ANB032, a BTLA Checkpoint Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion and Prevented Graft versus Host Disease (GvHD) in a Mouse Model

Hare et al., 2024

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduces T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1^high Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial

Luu et al., 2024

ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells: Results from a First-in-Human Phase 1 Study

Luu et al., 2023

Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial

Gudjonsson et al., 2021

AnaptysBio - Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial

Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial

Rosnilimab, a Depleter and Agonist Antibody Targeting PD-1+ T Cells, in Clinical Development for Ulcerative Colitis, Reduces Pathogenic PD-1+ T Cells and Inflammatory Cytokine Secretion in Patient Blood and in a Mouse Model of Colitis

Imsidolimab, an IL-36 Receptor Antagonist, was Effective and Well-Tolerated for Treatment, Maintenance of Response, and Prevention of Flares in Patients with Generalized Pustular Psoriasis: Results from the Phase 3 Trials, GEMINI-1 and GEMINI-2

ANB032, a BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology

ANB032, an Investigational BTLA Agonist Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and Prolonged Survival in a Mouse Model of Graph versus Host Disease (GvHD)

ANB032, an Investigational BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis (AD) Pathophysiology

Rosnilimab, a PD-1 Agonist Antibody that Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling

Optimizing PD-1 Agonist Signaling With Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

ANB032, a BTLA Checkpoint Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion and Prevented Graft versus Host Disease (GvHD) in a Mouse Model

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduces T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1^high Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial

ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells: Results from a First-in-Human Phase 1 Study

Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial

AnaptysBio, Inc.

Quick Links

Pipeline

Rosnilimab, a Selective and Potent Depleter of Pathogenic T Cells, Demonstrates Efficacy, Safety and Translational Proof of Mechanism in a Rheumatoid Arthritis Phase 2B Trial

Rosnilimab, a Depleter and Agonist Antibody Targeting PD-1+ T Cells, in Clinical Development for Ulcerative Colitis, Reduces Pathogenic PD-1+ T Cells and Inflammatory Cytokine Secretion in Patient Blood and in a Mouse Model of Colitis

Imsidolimab, an IL-36 Receptor Antagonist, was Effective and Well-Tolerated for Treatment, Maintenance of Response, and Prevention of Flares in Patients with Generalized Pustular Psoriasis: Results from the Phase 3 Trials, GEMINI-1 and GEMINI-2

ANB032, a BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis Pathophysiology

ANB032, an Investigational BTLA Agonist Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion, and Prolonged Survival in a Mouse Model of Graph versus Host Disease (GvHD)

ANB032, an Investigational BTLA Checkpoint Agonist Antibody, Attenuates Dendritic Cell (DC) Maturation and Function: A Novel Mechanism Addressing Atopic Dermatitis (AD) Pathophysiology

Rosnilimab, a PD-1 Agonist Antibody that Binds to a Membrane Proximal Epitope Leading to Optimized PD-1 Agonistic Signaling

Optimizing PD-1 Agonist Signaling With Membrane Proximal Binding of Rosnilimab, a Clinical Stage PD-1 Agonist IgG1 Antibody

ANB032, a BTLA Checkpoint Agonist Monoclonal Antibody, Reduced T Cell Proliferation, Inflammatory Cytokine Secretion and Prevented Graft versus Host Disease (GvHD) in a Mouse Model

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduces T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1high Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial

ANB032, a Novel BTLA Agonist Monoclonal Antibody, Inhibits T Cell Proliferation, Reduces Inflammatory Cytokines, and Down Modulates BTLA Expression on Circulating T and B Cells: Results from a First-in-Human Phase 1 Study

Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial

Rosnilimab, a Novel PD-1 Agonist Monoclonal Antibody, Reduces T Cell Proliferation, Inflammatory Cytokine Secretion, and PD-1^high Expressing CD4 and CD8 T Cells: Results From a Phase 1 Healthy Volunteer Clinical Trial